Could New Biomedical Research Shape the Future of the Placenta Market?

0
161

Placenta Market: Clinical Innovation Is Widening Medical Applications

The placenta market is no longer defined by cosmetics alone. Polaris Market Research values the global market at USD 652.21 million in 2025, with a projection of USD 1,404.87 million by 2034 at a CAGR of 8.9% during 2026–2034. Within the clinical segment, placenta-derived biologics and related therapies are attracting attention from hospitals, wound care providers, and biopharmaceutical developers.

Expanding Applications in Medicine and Wound Care

Placenta is increasingly used in regenerative medicine and wound healing, particularly for chronic wounds, burns, and orthopedic conditions. Placenta-derived biologics, including amniotic membrane products, placental stem cells, and extracellular matrix components, have demonstrated efficacy in accelerating tissue regeneration, reducing inflammation, and enhancing angiogenesis. These properties are valuable where conventional options, such as skin grafts or synthetic biologics, show limited success.

In chronic wound management, the rising incidence of diabetic foot ulcers, venous leg ulcers, and pressure ulcers fuels demand for placental allografts. According to MDPI, over 25% of diabetic foot ulcer cases lead to lower limb amputation if left untreated, increasing the need for advanced wound care. Products such as EpiFix (MiMedx), Affinity (Organogenesis), and AmnioBand (MTF Biologics) have gained market traction by promoting faster wound closure and reducing infection risks. Such dressings supply anti-inflammatory cytokines, growth factors, and extracellular matrix proteins that collectively enhance epithelialization, and hospitals, specialty wound care centers, and outpatient clinics are increasingly integrating amniotic membrane products and other placental biologics into standard treatment protocols.

Biopharmaceutical Innovation and Stem Cell Pipelines

The biopharmaceutical industry is investing in placental-derived therapeutics because the placenta is a rich source of stem cells and bioactive molecules. A key trend is the focus on autoimmune diseases, neurological disorders, and oncology, where placental stem cell therapies show strong potential.

Pluristem Therapeutics and Celularity are developing treatments for conditions such as Parkinson's disease, stroke recovery, and Crohn's disease. The US FDA's regenerative medicine advanced therapy (RMAT) designations are accelerating regulatory approval and commercialization. Pluristem's PLX-PAD is in clinical trials for muscle regeneration and critical limb ischemia, while Celularity's CYNK-001 is being tested for multiple myeloma and glioblastoma. Growing adoption of placental MSC-based approaches underscores the long-term interest in placental stem cell therapies.

Recent developments reinforce this direction. In January 2026, Pluri, Inc. completed the first phase of a collaboration with Resbiomed Technologies OOD to develop collagen-rich biomaterials from placenta tissue. In May 2025, Tehran University of Medical Sciences conducted a phase 1 clinical study of placenta-derived stem cells for multiple sclerosis, assessing safety and effectiveness in reducing inflammation and supporting nerve repair.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/placenta-market 

Pharmaceutical Segment and Regional Drivers

By application, the pharmaceuticals segment is expected to register a CAGR of 8.9% during the forecast period. Placental extracts have been explored for regenerative medicine, wound healing, and immune modulation, owing to bioactive molecules such as growth factors, cytokines, and extracellular vesicles. They have shown benefits in post-operative wound care and burn treatment by accelerating tissue repair. In Japan, injectable placental extract therapies are widely used for liver diseases and chronic fatigue syndrome. With over 6.7 million people in the US suffering from chronic non-healing wounds, the opportunity in advanced wound management continues to grow.

In Asia Pacific, which is forecast to grow at a CAGR of 9.1%, demand is supported by the rising prevalence of rare diseases such as muscular dystrophy. According to Parent Project Muscular Dystrophy, India alone has 327 cases of Duchenne muscular dystrophy in the last 15 years, representing 6% of cases worldwide. Placenta-derived therapies are gaining attention where conventional therapies have limited success.

Competitive Landscape

MIMEDX Group, Inc. focuses on placental tissue-based regenerative medicine and wound care solutions. Japan Bio Products Co., Ltd. offers Laennec, a human placental extract injection for liver function improvement, and Melsmon, a placental-derived injection for menopausal symptoms. Other key players include Japan Natural Laboratories Co., Ltd.; Albert David Limited; Atlanta Placenta Encapsulation; PURTIER Placenta; The Placenta Company; Smith and Nephew; Mommy Made Encapsulation; and Nubloom LLC. The report's contents also identify the high cost of placenta-based product development as a restraint.

Strategic Takeaway

For B2B decision-makers, clinical evidence, regulatory support, and adoption in standard care protocols will shape competitive positioning in medical applications.

Conclusion

The Placenta Market is gaining attention due to expanding research into regenerative medicine, wound care, and biomedical applications of placental tissues. Increasing interest in placenta-derived materials and their potential therapeutic applications is supporting industry development. Advancements in tissue processing, preservation technologies, and biotechnology research are creating opportunities for product innovation. Growing investments in regenerative healthcare and the development of specialized medical products further contribute to market expansion. However, ethical considerations, regulatory requirements, and clinical validation remain important challenges. The market's future growth will depend on continued scientific research, product safety, and successful commercialization of approved placenta-derived applications.

More Trending Latest Reports By Polaris Market Research:

Last Mile Delivery Market

South America Carbon Dioxide Market

Artificial Flowers Market

T4 DNA Ligase Market

South America Carbon Dioxide Market

Muscle Stimulator Market

Fraise Mowers Market

Declutter and Organize Your Garage with the Booming Garage Organization and Storage Market

U.S. Fiber Cement Market

Suche
Kategorien
Mehr lesen
Andere
Cervical Dysplasia Market Growth Driven by Cervical Health Awareness
Cervical Dysplasia Market Polaris Market Research presents its latest market research report,...
Von Nilam Jadhav 2026-08-31 11:28:29 0 636
Spiele
MLB The Show 25: Change Positions in Road to the Show
Navigating your career path in MLB The Show 25's Road to the Show can be challenging, especially...
Von Xtameem Xtameem 2025-10-30 04:55:44 0 909
Andere
Top Reasons to Choose Modern Window Blinds for Your Home
Choosing the proper window coverings can remodel a home, and shutter blinds...
Von JJ All Blinds 2026-08-07 03:57:49 0 1KB
Andere
Sufentanil Market Size, Share, Trends, Demand, Growth and Competitive Analysis
"Executive Summary Sufentanil Market : The global sufentanil market size was valued at...
Von Nshita Hande 2025-07-21 09:40:47 0 1KB
Art & Design
Global Microcrystalline Cellulose Market Forecast 2024–2032: Size, Share, Trends & Growth
Polaris Market Research announces the release of its latest research report Microcrystalline...
Von Prajwal Agale 2026-09-01 11:11:14 0 229